STAT+: GLP-1s are given an FDA warning for rare eye condition risk

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got lots of news that we’ll get straight into.

The need-to-know this morning

• Beam Therapeutics said its CRISPR-based treatment for sickle cell disease achieved the primary goal of a pivotal clinical trial — freedom from severe pain crises for at least 12 months. No detailed data were disclosed, but Beam said it would file an FDA marketing application for the therapy, called risto-cel, as soon as the end of this year.

PepGen shows promising data for muscular dystrophy 

The biotech company PepGen said this morning that its experimental drug had shown, by one key measure, the most promising early data yet in the race to treat a commmon type of muscular dystrophy.

Continue to STAT+ to read the full story…